A novel experimental drug is demonstrating encouraging results through its final phase of human clinical trials. Filgotinib is a JAK inhibitor selectively targeting the JAK1 enzyme. It is chiefly being investigated for the rheumatoid arthritis treatment, but initial clinical trials have encouraged for treatment of ulcerative colitis and Crohn's disease.
After years of development, scientists are going to publish some of the first observations from the final Phase 3 human trials into the new drug efficacy, ahead of an FDA application for moving the drug to market by 2020.
Principle investigator on clinical trial study suggested that these results are way better than any of the current first-generation JAK inhibitors which are already available clinically. He also observes that the new drug seems effective regardless of any other treatments a patient had previously undergone and failed.
This is unlike any of the traditional biological treatments for rheumatoid arthritis where subsequent therapies are rarely as valuable and efficacious as the first therapy a patient is being administered on.
Clinical Research Newsletter
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like